Trial Profile
A Phase-IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of Golimumab (MK-8259 [SCH 900259]) After Treatment Withdrawal, Compared With Continued Treatment (Either Full- or Reduced-Treatment Regimen), In Subjects With Non-Radiographic Axial Spondyloarthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Dec 2022
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Non-radiographic axial spondyloarthritis; Spondylarthritis
- Focus Therapeutic Use
- Acronyms GO-BACK
- Sponsors Merck Sharp & Dohme Corp.
- 14 Nov 2022 Primary endpoint has been met (Percentage of Participants Without a Disease Activity Flare During Period 2) , according to Results presented at the ACR Convergence 2022
- 14 Nov 2022 Results presented at the ACR Convergence 2022
- 30 Mar 2021 Status changed from active, no longer recruiting to completed.